The Drug Controller General of India has ordered Sun Pharmaceutical, the country's largest drug maker by market capitalisation, to suspend clinical research activities at its Mumbaibased bio-analytical laboratory, a move that could slow down the company's regulatory filings in India and possibly overseas as well. According to officials familiar with the matter, the drug regulator took the step after discovering that Sun didn't have the requisite approval from the central government for operating the laboratory. The drug regulator has decided not to accept future applications and won't process existing new drug filings that Sun has made from the Mumbai lab until the company gets an approval.
Help employers find you! Check out all the jobs and post your resume.
